Veracity Capital’s Cytokinetics CYTK Stock Holding History

Veracity Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$632K	Buy	7,419 +5	+0.1%	+$359	0.17%	116
2026 Q1	$489K	Hold	7,414	–	–	0.17%	119
2025 Q4	$471K	Hold	7,414	–	–	0.14%	149
2025 Q3	$407K	Hold	7,414	–	–	0.13%	163
2025 Q2	$245K	Hold	7,414	–	–	0.08%	207
2025 Q1	$298K	Hold	7,414	–	–	0.12%	172
2024 Q4	$349K	Hold	7,414	–	–	0.13%	158
2024 Q3	$391K	Hold	7,414	–	–	0.15%	142
2024 Q2	$402K	Sell	7,414 -14	-0.2%	-$845	0.17%	126
2024 Q1	$521K	Sell	7,428 -50	-0.7%	-$3.87K	0.2%	114
2023 Q4	$624K	Buy	7,478 +44	+0.6%	+$1.59K	0.25%	88
2023 Q3	$219K	Sell	7,434 -72	-1%	-$2.4K	0.1%	178
2023 Q2	$245K	Buy	7,506 +32	+0.4%	+$1.18K	0.1%	188
2023 Q1	$263K	Sell	7,474 -34	-0.5%	-$1.39K	0.12%	168
2022 Q4	$344K	Buy	7,508 +7	+0.1%	+$301	0.16%	131
2022 Q3	$363K	Sell	7,501 -820	-10%	-$39.5K	0.2%	112
2022 Q2	$327K	Hold	8,321	–	–	0.17%	130
2022 Q1	$306K	Hold	8,321	–	–	0.13%	171
2021 Q4	$379K	Hold	8,321	–	–	0.15%	148
2021 Q3	$297K	Buy	+8,321	New	+$245K	0.13%	178
2021 Q2	–	Sell	-9,715	Closed	-$226K	–	266
2021 Q1	$226K	Buy	+9,715	New	+$207K	0.1%	199

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Veracity Capital's CYTK Position: Q2 2026 in Review

Veracity Capital increased its Cytokinetics (CYTK) stake by 0.07% in Q2 2026, buying an estimated $359 and bringing the position to 7,419 shares worth $632K. The position accounts for 0.17% of the portfolio, ranked #116.

Veracity Capital first reported a position in CYTK in Q1 2021 and has held it in 21 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Veracity Capital held 7,419 shares of Cytokinetics worth $632K as of Q2 2026.
Veracity Capital bought 5 Cytokinetics shares in Q2 2026, an estimated $359.
Cytokinetics made up 0.17% of Veracity Capital's portfolio in Q2 2026, its #116 holding.
Veracity Capital first reported a position in Cytokinetics in Q1 2021 and has held it in 21 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Veracity Capital's 13F filing for Q2 2026, filed 13 Jul 2026.